[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Western Institute for Veterans Research\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100487326","phase-2-human-papillomavirus-hpv-vaccination-vs-placebo-for-the-treatment-of-refractory-cutaneous-warts-100487326",false,"NCT05625633","Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts","Human Papillomavirus (HPV) Vaccination for the Treatment of Refractory Cutaneous Warts: A Randomized, Placebo-Controlled, Double-Blinded Trial","Inclusion Criteria:\n\n1. Must be able to understand and provide written informed consent\n2. Age 18 or older\n3. Clinical diagnosis of cutaneous warts\n4. Must have received prior treatment for cutaneous warts (such as curettage, cryotherapy, salicylic acid, intralesional Candida antigen injection, etc.)\n\nExclusion Criteria:\n\n1. Untreated cutaneous warts\n2. Anogenital warts\n3. Oral warts\n4. Treatment for cutaneous warts in the past 4 weeks\n5. Active acute illness\n6. Immunosuppression\n7. Known hypersensitivity to HPV vaccination\n8. Subjects may not receive any other investigational treatment\n9. Pregnancy or planned pregnancy during the study period","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.",[27],"Warts",[29,30,31],"Refractory cutaneous warts","Human Papillomavirus (HPV) Vaccination","HPV vaccine","RECRUITING","2024-04-04",{"date":35,"type":36},"2024-04-05","ACTUAL",{"date":38,"type":36},"2024-03-25",{"date":40,"type":20},"2026-12",{"name":42,"class":43},"Western Institute for Veterans Research","OTHER",2,""]